Stocks Nab Fresh Midday Records As Optimism Grows

Meanwhile, one of the worst performers on the Nasdaq is biotech concern Erytech Pharma SA (Nasdaq: ERYP). The equity was last seen down 16.3% to trade at $9.69, after announcing its TRYbeCA-1 Phase 3 trial in patients with 2L pancreatic cancer will continue to final analysis. The drop has ERYP set for its first close below the formerly supportive 40-day moving average in over three months. Year-over-year, the security remains up 41.6%.

ERYP Chart Feb 8

1 2
View single page >> |

Disclaimer: Schaeffer's Investment Research ("SIR" or "we" or "us") is not registered as an investment adviser. SIR relies upon the "publishers' ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.